Navigation Links
SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
Date:11/17/2011

MILFORD, Mass., Nov. 17, 2011 /PRNewswire/ -- SeraCare Life Sciences, Inc. (NASDAQ: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today reported financial results for its 2011 fiscal fourth quarter and year ended September 30, 2011.

(Logo: http://photos.prnewswire.com/prnh/20110324/NE70714LOGO)

"During the fourth quarter, we drove an improvement in the direction of our product sales, halting a four-quarter trend of year-over-year declines," said Greg Gould, Interim President, Chief Executive Officer and Chief Financial Officer. "We believe this improvement is a direct result of our new sales strategy. Specifically, we executed on a high-touch customer interaction initiative to educate key accounts on the full scope of our product portfolio and to deliver exceptional service—resulting in new sales opportunities from existing customers. In addition, we continued to expand our offerings by introducing 12 new products designed to improve patient care during the quarter. We introduced 24 new products in fiscal 2011.

"While, as anticipated, revenues are down in comparison to fiscal year 2010, we have made significant progress in our underlying business operations," said Gould. "We are confident that the actions we're taking and the momentum we are generating will lead to improved top and bottom line financial performance in 2012."  

For the quarter ended September 30, 2011, SeraCare reported revenue of $11.0 million, a 17.3 percent decrease compared to $13.3 million in revenue for the quarter ended September 30, 2010. Gross margins remained relatively flat at 39.0 percent, compared to 39.1 percent for the same quarter in the prior year. The Company reported a net loss of $831,000, or ($0.04) per share on a basic and diluted ba
'/>"/>

SOURCE SeraCare Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. SeraCare Life Sciences Secures $20 Million Credit Facilities
2. SeraCare Life Sciences to Report First Quarter 2011 Financial Results on February 11, 2011
3. SeraCare Reports First Quarter Fiscal Year 2011 Results
4. SeraCare Life Sciences Appoints Sean OConnor as Vice President of Sales and Marketing
5. SeraCare Announces the Election of Joseph Nemmers and Kevin Hrusovsky to the Board of Directors
6. SeraCare Reports Second Quarter Fiscal Year 2011 Financial Results
7. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
8. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
9. Par Pharmaceutical Reports Second Quarter 2008 Results
10. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
11. Pharmos Corporation Reports 2008 Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... Toronto Stock Exchange Symbol: MS, EDMONTON, June 12 /PRNewswire-FirstCall/ - ... multiple sclerosis (MS), today,announced that Mr. Kevin Giese, President and CEO, ... in San Diego,California., WHEN: ... (PDT), WHERE: ...
... June 12 Repligen Corporation,(Nasdaq: RGEN ) today ... ended March 31, 2008. Total revenue for fiscal year ... fiscal year 2007,ended March 31, 2007, an increase of ... of Protein A and SecreFlo(R) product revenue., Operating ...
... concerning the,economic and business growth in the Tampa Bay ... To Connect Tampa Bay With Mexico, South America, ... cargo service every 60,days between the Port of Tampa ... and Iquitos, Peru. Headquartered in,Lima, Peruvian Amazon Line has ...
Cached Biology Technology:BioMS Medical to present at 2008 BIO International Convention 2Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 2Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 3Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 4Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 5Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 6Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 7Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 8Highlights of Economic and Business Growth in the Tampa Bay Region 2Highlights of Economic and Business Growth in the Tampa Bay Region 3
(Date:4/24/2014)... bacteria attack plants, they often inject harmful proteins ... suppress natural defenses. However, in some plants, bacteria ... a potential host. Now, researchers at the University ... that allows the bacteriaknown mostly for attacking tomatoesto ... natural anti-infective treatments that work with food-producing plants ...
(Date:4/24/2014)... April 24, 2014GEN Publishing recently introduced ... focusing on the application of OMICs technologies in ... sequencing, are beginning to transform medical care just ... the past decade-and-a-half. , "GEN,s editors and reporters ... genomics, metabolomics, transcriptomics, etc. etc. for years," said ...
(Date:4/24/2014)... 24, 2014D-ribose is a commercially important sugar used ... a starting compound for synthesizing riboflavin and several ... to increase the bacteria,s ability to produce ... efficient industrial-scale production of this valuable chemical, as ... , a peer-reviewed journal from Mary Ann Liebert, ...
Breaking Biology News(10 mins):Plants send out signals attracting harmful bacteria, MU study finds 2
... her research into single-cell organisms that affect oral health, ... molecular genetics at The University of Texas Health Science ... the 2011 American Society for Microbiology (ASM) Founders Distinguished ... made significant contributions to the society. Goldschmidt joined the ...
... The University of Pennsylvania, Dr. Ron Koder, assistant professor of ... of a team that devised a novel method for producing ... neuroglobin. He was recently awarded a three-year $1.3 million ... artificial blood that can be administered to injured troops on ...
... Biomedical Research Institute (Seattle BioMed) and Northwestern University Feinberg ... the effort to wipe out some of the most ... large structural genomics centers, they,ve experimentally determined 500 three-dimensional ... pathogens, which could potentially lead to new drugs, vaccines ...
Cached Biology News:UTHealth professor to receive service award from American Society for Microbiology 2CCNY professor gets grant to develop 'artificial blood' 2Milestone in fight against deadly disease 2Milestone in fight against deadly disease 3
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... patented technology, the Lone Wolf valve has ... Open proportional valve available on the market. ... repeatable high-speed performance, and ensures maximum accuracy., ... Enhances system control and patient comfort. , ...
... The VSO LF (Low Flow) offers the same ... control for applications where control is critical or ... solenoid-operated valve automates the flow of gas in ... either DC current or pulse width modulation; closed ...
... from non-demolished blood that is ... The donors are not medicated ... maintained on an antibiotic free ... : 85 mg/ml (by Refractometry).Strain: ...
Biology Products: